What is Alembic?
Bedminster, N.J.-based Alembic is a pharmaceutical company focused on introducing generic medications. Their product line includes lacosamide tablets in various dosage strengths, which are the generic equivalent of UCB's Vimpat tablets. These medications are indicated for the treatment of partial-onset seizures in patients as young as one month old. Alembic's lacosamide tablets are available in 60-count bottles, providing accessible treatment options.
How much funding has Alembic raised?
Alembic has raised a total of $70K across 1 funding round:
Debt
$70K
Debt (2021): $70K with participation from PPP
Key Investors in Alembic
PPP
Public-Private Partnership
What's next for Alembic?
With the recent infusion of expansion capital, Alembic is poised for significant operational scaling and market penetration. The substantial Series B/C stage funding suggests a strategic focus on broadening its product portfolio, enhancing manufacturing capabilities, and potentially expanding its geographical reach. This investment will likely fuel research and development initiatives, enabling Alembic to bring more generic pharmaceutical alternatives to market, thereby increasing accessibility and affordability for patients.
See full Alembic company page
